Adragos Pharma is a contract development and manufacturing organization (CDMO) that provides development and manufacturing services for drug products. It concentrates on small molecule dosage forms including sterile and non-sterile liquids, solids, and...
Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.
Bora Pharmaceuticals Co., Ltd. yesterday (April 1) finalized the acquisition of Upsher-Smith Laboratories, Inc., a leading generics manufacturer based in Minnesota, U.S., from its previous owners, Sawai Group Holdings and Sumitomo Corporation of Americas.
Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Announced today (January 25), Quibim, a company transforming imaging data into actionable predictions of cancer progression and treatment responses, has partnered with Merck KGaA.
Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
With innovative and flexible lab and manufacturing solutions being a critical success factor in drug development and delivery, SmartLabs, was delighted to announce the raise of $48 million series C financing.
An alliance between KBI Biopharma Inc., and Argonaut Manufacturing Services Inc., has been formed so biopharma clients can receive end-to-end drug substance and drug product manufacturing solutions.
Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a €10 million deal.
Pharma giant, GSK, plans to invest £200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (£870 million).
Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
AION Labs, the first-of-its-kind venture studio today (January 8) announced its new partnership with Amiti Ventures, a leading early-stage venture capital firm in Israel.
Bristol Myers Squibb has announced it has acquired Karuna Therapeutics, Inc., for a total equity value of $14 billion or $12.7 billion net of estimated cash.
Decentralized clinical trials (DCTs) are gaining increasing interest as they have the potential to make clinical trial operations quicker, more efficient and more accessible to patients. Check out five DCT organizations that have raised big venture capital...
The pharmaceutical industry in 2023 has seen many investments, partnerships, acquisitions and more. As the year ends, industry leaders give the biggest trends to look for in 2024, with artificial intelligence being a hot topic.
A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
Definitive agreements with Fresenius Kabi have been signed by Prange Group and its affiliate Adragos Pharma for its sterile pharmaceutical production site in Halden, Norway.
Life sciences investment group and part of global investment firm Carlyle, Abingworth announced last week it had exceeded its $300 million target by $56 million.
A transaction between Citius Pharmaceuticals and TenX Keane which will result in the formation of Citius Oncology, Inc. is due to close in the first half of next year (2024).
A collaboration has been formed between the US pharmacy chain Walgreens and the Cardiovascular Research Foundation (CRF) to measure how prevalent valvular heart disease (VHD) is among older Americans.
Technology company, Medable Inc., offering services for modern clincal trials has joined forces with Pluto Health, a smart care coordination services company offering a health coordination platform.
Danaher is to acquire Abcam for $24 per share - a total enterprise value of approximately $5.7 billion representing approximately 40% more than Abcam's undisclosed share prices in May.
STARLIMS, a company that provides enterprise informatics solutions has acquired Labstep, a research and development (R&D) electronic laboratory notebook (ELN).
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
The Swiss company Idorsia has sold its operating businesses Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd to the Japanese firm Sosei Heptares for CHF 400 million ($466 million).
The US drug developer Nanopharmaceutics has teamed up with PrecisionLife in a strategic collaboration to accelerate the development of Nanopharmaceutics’ central nervous system (CNS) drug pipeline with precision medicine.
The Japanese company Shionogi has taken over the US biotech Qpex Biopharma for up to $140 million in a bid to expand its pipeline of antimicrobial drugs and boost its R&D muscle in infectious disease.
A soft mist inhaler made by Resyca BV, a joint venture of Medspray Pharma BV and Recipharm AB, is being brought to patients with pulmonary arterial hypertension (PAH).
Multinational pharmaceutical company, Gedeon Richter UK Ltd, announced this week that it has acquired full marketing and distribution rights to a contraceptive range.
Slope, a site-first organization, ‘eliminating the chaos’ impacting clinical trials has joined CancerX as a founding member of The White House’s national Cancer Moonshot.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight...
The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.
Only a few months after being bought out, the CDMO invests in its capabilities with a facility to support drug-device products and sterile fill-finish.
The Institute for Population and Precision Health (IPPH) at the University of Chicago has joined private biotech company, Freenome, to become its partner as part of a study.
